Anuh Pharma Announces FY26 Results, Recommends Rs. 1.50 Dividend; Confirms Key Leadership Appointments
Anuh Pharma Limited announced several material corporate updates following its Board of Directors meeting held on May 20, 2026. The Board approved the audited financial results for the quarter and full financial year ended March 31, 2026, and recommended a dividend of Rs. 1.50 per equity share.Financial Performance Highlights
The Company released the audited financial results for the quarter and the year ending March 31, 2026.According to the reported figures (in Rs. Lakhs), the total revenue for the 12 months ended March 31, 2026, reached 77,601.30. Total expenses for the same period were 72,179.16, leading to a Profit/(Loss) after Tax of 4,104.61. The total comprehensive income for the year was 4,123.12.
The financial performance data is summarized below:
| Particulars | 3 Months ended 31/03/2026 | 12 Months ended 31/03/2026 | 3 Months ended 31/03/2025 | 12 Months ended 31/03/2025 |
|---|---|---|---|---|
| Total Revenue | 20,086.26 | 77,601.30 | 19,953.78 | 67,097.02 |
| Total Expenses | 18,534.31 | 72,179.16 | 18,225.81 | 60,996.49 |
| Profit/(Loss) after Tax | 1,168.14 | 4,104.61 | 1,245.70 | 4,735.19 |
The Board of Directors recommended a dividend of Rs. 1.50 per Equity share. This represents a 30% payout based on the face value of Rs. 5 per share for the financial year ended March 31, 2026. This proposed dividend is subject to approval at the ensuing Annual General Meeting (AGM).
Board and Management Changes
The Board meeting also saw several key appointments and re-appointments:- Director Re-appointments: Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal were re-appointed as Non-Executive Non-Independent Directors, subject to shareholder approval at the AGM.
- Quality Leadership: The Company appointed Mr. P. N. Rao as General Manager - Quality, effective from June 1, 2026. Mr. P. N. Rao brings over 23 years of experience in quality leadership within the pharmaceutical manufacturing sector.
- Audit Appointments:
* Ankit Kishor Chande, Cost Accountant, was appointed as the Cost Auditor for the Financial Year 2026-27.
Shareholder Promoter Status Update
The Company disclosed requests received from shareholders forming part of the Promoter Group seeking re-classification of their status from 'Promoter Group' to 'Public' category. The total number of equity shares held by the listed shareholders for this purpose is 9,49,988, representing a 0.95% shareholding.| Name | Number of Equity shares held | % of shareholding |
|---|---|---|
| Madhurika Narendra Shah | 12,000 | 0.01 |
| Hemant Babubhai Choksi | 24,000 | 0.02 |
| Mukesh Kantilal Shah | 14,400 | 0.01 |
| Aruna Navnit Shah | 5,040 | 0.01 |
| Vikram Kirtilal Shah | 200 | 0 |
| Kiran Piyush Shah | 15,388 | 0.02 |
| Kinjal Siddharth Jhaveri | 8,16,160 | 0.81 |
| Nina Vijay Shah | 60,000 | 0.06 |
| Neela Pradeep Shah | 2,800 | 0.003 |
Annual General Meeting Details
The 66th Annual General Meeting (AGM) of Anuh Pharma Limited is scheduled for Wednesday, August 12, 2026, via Video Conferencing (VC)/Other Audio Visual Means (OAVM).Key dates related to the AGM include:
- Record Date (Final Dividend Eligibility): Wednesday, August 5, 2026.
- Record Date (Voting): Wednesday, August 5, 2026.
- Record Book Closure: The Register of Members and Share Transfer Books will remain closed from August 6, 2026, to August 12, 2026.
Additionally, the Board approved the adoption of a new set of Memorandum of Association ('MOA') and Articles of Association ('AOA') of the Company, subject to shareholder approval.
ANUHPHR Stock Price Movement
On Wednesday, Anuh Pharma Limited shares edged higher, settling at ₹81.19 and completing the trading day with a solid gain of 2.18%. The stock saw notable interest during the session, underpinned by a trading volume of 71,721 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: